Theratechnologies - CEO, Paul Lévesque.
CEO, Paul Lévesque.
Source: Theratechnologies.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category
  • The ADRIQ rewards Quebec-based companies for leadership in innovation in their respective fields
  • Earlier this year, the company received the F.D.A.’s fast-track designation for TH1902 for the treatment of advanced and recurrent solid tumors expressing the sortilin receptor
  • Theratechnologies commercializes two medicines in HIV and has research programs in NASH, oncology and HIV
  • Theratechnologies (TH) closed down by 1.86 per cent trading at $4.21 per share

Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category.

The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective fields.

At the beginning of 2021, Theratechnologies received the F.D.A.’s fast-track designation for TH1902 for the treatment of advanced and recurrent solid tumors expressing the sortilin receptor.

TH1902 is a peptide-drug conjugate derived from the company’s oncological SORT1+ technology. It combines a proprietary peptide with docetaxel.

The company’s research has been partially funded by The Canadian Cancer Society and the government of Quebec.

Paul Lévesque, President and CEO of Theratechnologies, stated,

“It is quite rare to obtain the fast-track designation this early in the drug development process and this was achieved through spectacular preclinical data. We are very proud of this achievement and look forward to the future with great hope for patients.”

The 31st ADRIQ Innovation Awards Gala was held on November 25, 2021.

Theratechnologies commercializes two medicines in HIV and has research programs in NASH, oncology and HIV.

Theratechnologies (TH) closed down by 1.86 per cent trading at $4.21 per share.

More From The Market Herald

" Medicenna (TSX:MDNA) announces publication of MDNA11 preclinical data

Medicenna Therapeutics Corp. (MDNA) announced the publication of preclinical data on MDNA11.

" Clearmind Medicine (CSE:CMND) engages the Independent Trading Group as a market maker and Thunder11 as a PR agency

Clearmind Medicine Inc. (CMND) has engaged the services of Independent Trading Group to provide market-making services.

" Psyched Wellness (CSE:PSYC) provides update on study with the National Research Council of Canada

Psyched Wellness (PSYC) has released preliminary data from its study with the National Research Council of Canada (NRC).
codikoat, covid protection

" PharmaDrug (CSE:PHRX) begins manufacturing PD-001 for treatment of rare cancers and COVID-19

PharmaDrug (PHRX) has begun manufacturing PD-001, its oral formulation of cepharanthine, for cancer and infectious disease studies.